Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P22891
UPID:
PROZ_HUMAN
Alternative names:
-
Alternative UPACC:
P22891; A6NMB4; Q15213; Q5JVF5; Q5JVF6
Background:
Vitamin K-dependent protein Z plays a crucial role in blood coagulation, acting as a regulatory factor in the intricate balance of hemostasis. It functions by binding thrombin and enhancing its association with phospholipid vesicles, alongside inhibiting the coagulation protease factor Xa in a complex with SERPINA10, calcium, and phospholipids. This protein's unique mechanism underscores its importance in the coagulation cascade.
Therapeutic significance:
Understanding the role of Vitamin K-dependent protein Z could open doors to potential therapeutic strategies. Its pivotal function in regulating blood coagulation presents an opportunity for developing novel treatments for coagulation disorders.